Bilal Mazhar Qureshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bilal Mazhar Qureshi has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Nadeem Abbasi
Section Head Radiation Oncology, Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan
9 shared publicationsNasir Ali
Section Head Radiation Oncology, Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan
9 shared publicationsAsim Hafiz
Section Head Radiation Oncology, Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan
8 shared publicationsMaria Tariq
Radiation Oncology Section Department of Oncology Aga Khan University Hospital Karachi Pakistan
6 shared publications- Jeannette Parkes
Department of Radiation Oncology University of Cape Town and Groote Schuur Hospital Cape Town South Africa
5 shared publications - Muhammad Atif Mansha
Department of Radiation Oncology, Dow University of Health Sciences, Karachi, Pakistan
5 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Bridging Guidelines and Practice: A Web-Based Survey of Barriers to Guideline-Concordant Colorectal Cancer Care in Pakistan
Introduction: Colorectal cancer (CRC) is the second most common cancer in Pakistan. Evidence-based guidelines are essential for standardizing care, but implementation may be constrained by limited resources. We evaluated CRC guideline use and implementation barriers among clinicians in Pakistan.Methods: We conducted a cross-sectional online survey of clinicians involved in CRC care across public and private healthcare institutions in Pakistan, following the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). A structured questionnaire was distributed via email and social media over three months. The survey assessed participant characteristics, awareness and use of CRC guidelines, implementation barriers, and availability of diagnostic and treatment resources. Responses were analyzed using descriptive statistics, summarized overall and by practice setting.Results: 54 clinicians completed the survey; 65% were surgeons, 19% radiation oncologists, and 17% medical oncologists. Most practiced in Sindh (57%) or Punjab (28%), and 46% worked primarily in public hospitals. Overall, 94% were aware of CRC guidelines, although only 39% were aware of local Pakistani guidelines. 80% reported frequent guideline use, with the US based National Comprehensive Cancer Network guideline most commonly used (76%). Best available evidence was the most common reason for guideline selection (65%). Most respondents (96%) encountered implementation barriers. Financial constraints were the most commonly reported barrier overall (77%), whereas patient clinical and behavioral factors predominated in public hospitals (76%). CT scanning (100%) and colorectal surgery services (98%) were consistently available.Conclusion: Although guideline awareness was high, substantial barriers to guideline-concordant CRC care persisted and varied across practice settings, highlighting financial, patient-related, and health-system constraints.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBridging Guidelines and Practice: A Web-Based Survey of Barriers to Guideline-Concordant Colorectal Cancer Care in Pakistan
Introduction: Colorectal cancer (CRC) is the second most common cancer in Pakistan. Evidence-based guidelines are essential for standardizing care, but implementation may be constrained by limited resources. We evaluated CRC guideline use and implementation barriers among clinicians in Pakistan.Methods: We conducted a cross-sectional online survey of clinicians involved in CRC care across public and private healthcare institutions in Pakistan, following the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). A structured questionnaire was distributed via email and social media over three months. The survey assessed participant characteristics, awareness and use of CRC guidelines, implementation barriers, and availability of diagnostic and treatment resources. Responses were analyzed using descriptive statistics, summarized overall and by practice setting.Results: 54 clinicians completed the survey; 65% were surgeons, 19% radiation oncologists, and 17% medical oncologists. Most practiced in Sindh (57%) or Punjab (28%), and 46% worked primarily in public hospitals. Overall, 94% were aware of CRC guidelines, although only 39% were aware of local Pakistani guidelines. 80% reported frequent guideline use, with the US based National Comprehensive Cancer Network guideline most commonly used (76%). Best available evidence was the most common reason for guideline selection (65%). Most respondents (96%) encountered implementation barriers. Financial constraints were the most commonly reported barrier overall (77%), whereas patient clinical and behavioral factors predominated in public hospitals (76%). CT scanning (100%) and colorectal surgery services (98%) were consistently available.Conclusion: Although guideline awareness was high, substantial barriers to guideline-concordant CRC care persisted and varied across practice settings, highlighting financial, patient-related, and health-system constraints.
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70469
SIOP Standards Framework for Pediatric Oncology Units in Low‐ and Middle‐Income Countries
Although standards exist for pediatric oncology units (POUs) in high‐income countries, their applicability in low‐ and middle‐income countries (LMICs) remains limited. Therefore, SIOP led a multidisciplinary global expert group to develop a practical, scalable, implementable, and evidence‐informed standards framework for POUs in LMICs. These standards prioritize key areas of practice, including infrastructure, clinical care practice, medication safety, research, and multidisciplinary coordination, with the aim of reducing variation and advancing equitable care. This work aligns with the World Health Organization (WHO) Global Initiative for Childhood Cancer's goal of achieving 60% survival by 2030.
- 29 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70469
SIOP Standards Framework for Pediatric Oncology Units in Low‐ and Middle‐Income Countries
Although standards exist for pediatric oncology units (POUs) in high‐income countries, their applicability in low‐ and middle‐income countries (LMICs) remains limited. Therefore, SIOP led a multidisciplinary global expert group to develop a practical, scalable, implementable, and evidence‐informed standards framework for POUs in LMICs. These standards prioritize key areas of practice, including infrastructure, clinical care practice, medication safety, research, and multidisciplinary coordination, with the aim of reducing variation and advancing equitable care. This work aligns with the World Health Organization (WHO) Global Initiative for Childhood Cancer's goal of achieving 60% survival by 2030.
- Open Access
- 8 May 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 7
Late effects in childhood cancer survivors: A global call to action based on the PENTEC initiative
- 8 May 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 7
Open AccessLate effects in childhood cancer survivors: A global call to action based on the PENTEC initiative
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500499
Advancing Pediatric Cancer Care in Asia: Outcomes From the 17th Annual SIOP Asia Congress, Riyadh, Saudi Arabia
The 17th Annual Congress of the Asian Society of Pediatric Oncology (SIOP Asia) was held in Riyadh, Saudi Arabia, from April 12 to 15, 2025, marking its first hosting in the Kingdom. Organized in collaboration with the Saudi Pediatric Hematology Oncology Society and global partners, the congress convened over 500 delegates from 45 countries under the theme “Stronger Together.” The scientific program featured nearly 70 invited speakers across five tracks: hematologic malignancies, solid tumors, neuro-oncology, precision medicine, and survivorship alongside multidisciplinary sessions in surgery, radiation oncology, nursing, and pharmacy. A total of 347 abstracts from 34 countries were submitted; 267 were accepted as posters, and 17 as oral presentations. Education Day, organized through SIOP's Disease-Specific Portal for Learning and Networking (DiSPLeN), provided case-based training to over 200 delegates comprising fellows along with junior and senior multidisciplinary participants emphasizing applicability in low-resource settings. Key congress themes included improving diagnostic equity, access to essential medicines, and strengthening regional research capacity. Presentations highlighted molecularly driven diagnostics such as FOXO1 fusion testing in rhabdomyosarcoma and LOGIC assays for constitutional mismatch repair deficiency, with emphasis on affordable applications in low- and middle-income countries (LMICs). Access to chemotherapy was addressed through the WHO/St Jude Global Platform for Childhood Cancer Medicines, offering sustainable, centralized procurement for LMICs. The need for expanded multicenter clinical trials was underscored, with initiatives such as the Asian Pediatric Hematology and Oncology Group, SIOP's Programme for Advancing Research Capacity, and collaborative tumor boards providing frameworks for progress. Surgical and radiation oncology sessions showcased pragmatic adaptations of advanced technologies, whereas survivorship and genetics sessions highlighted cancer predisposition syndromes and long-term quality-of-life challenges. The Riyadh congress reaffirmed that survival disparities in Asia are driven by addressable inequities. By advancing diagnostics, medicines, registries, and collaborative trials, SIOP Asia and its partners demonstrated a pathway toward narrowing the survival gap.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500499
Advancing Pediatric Cancer Care in Asia: Outcomes From the 17th Annual SIOP Asia Congress, Riyadh, Saudi Arabia
The 17th Annual Congress of the Asian Society of Pediatric Oncology (SIOP Asia) was held in Riyadh, Saudi Arabia, from April 12 to 15, 2025, marking its first hosting in the Kingdom. Organized in collaboration with the Saudi Pediatric Hematology Oncology Society and global partners, the congress convened over 500 delegates from 45 countries under the theme “Stronger Together.” The scientific program featured nearly 70 invited speakers across five tracks: hematologic malignancies, solid tumors, neuro-oncology, precision medicine, and survivorship alongside multidisciplinary sessions in surgery, radiation oncology, nursing, and pharmacy. A total of 347 abstracts from 34 countries were submitted; 267 were accepted as posters, and 17 as oral presentations. Education Day, organized through SIOP's Disease-Specific Portal for Learning and Networking (DiSPLeN), provided case-based training to over 200 delegates comprising fellows along with junior and senior multidisciplinary participants emphasizing applicability in low-resource settings. Key congress themes included improving diagnostic equity, access to essential medicines, and strengthening regional research capacity. Presentations highlighted molecularly driven diagnostics such as FOXO1 fusion testing in rhabdomyosarcoma and LOGIC assays for constitutional mismatch repair deficiency, with emphasis on affordable applications in low- and middle-income countries (LMICs). Access to chemotherapy was addressed through the WHO/St Jude Global Platform for Childhood Cancer Medicines, offering sustainable, centralized procurement for LMICs. The need for expanded multicenter clinical trials was underscored, with initiatives such as the Asian Pediatric Hematology and Oncology Group, SIOP's Programme for Advancing Research Capacity, and collaborative tumor boards providing frameworks for progress. Surgical and radiation oncology sessions showcased pragmatic adaptations of advanced technologies, whereas survivorship and genetics sessions highlighted cancer predisposition syndromes and long-term quality-of-life challenges. The Riyadh congress reaffirmed that survival disparities in Asia are driven by addressable inequities. By advancing diagnostics, medicines, registries, and collaborative trials, SIOP Asia and its partners demonstrated a pathway toward narrowing the survival gap.
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70213
Experience of Pediatric Radiation Oncology Peer Review Meetings: First Step Toward Centralizing Pediatric Radiotherapy in Pakistan
Introduction: Stark disparities in pediatric cancer outcomes persist between high and low sociodemographic index (SDI) regions due to fragmented healthcare systems and limited subspecialty expertise. In Pakistan, where pediatric radiation oncology expertise is not widely available, ensuring quality assurance (QA) is critical to mitigate errors that can lead to suboptimal treatment outcomes and long‐term consequences in children. To address this, virtual Pediatric Radiation Oncology Peer Review Meetings (PROPRMs) were initiated in 2022 to foster collaborative decision‐making and standardize treatment across the country. Methods: This study analyzed data from June 2022 to March 2025 from virtual PROPRM sessions organized by the Aga Khan University Hospital. Multidisciplinary meetings involving radiation and pediatric oncologists from multiple centers across the country transitioned from monthly to fortnightly. Case volume, clinical diagnoses, and management adjustments were documented and analyzed using descriptive statistics. Results: A total of 130 cases were reviewed across 46 sessions. The most common diagnostic categories were soft‐tissue sarcomas (33.8%) and bone tumors (16.2%). Notably, consensus‐driven changes in management were recommended in 70.8% of cases. The primary modifications (43.1%) directly involved radiation therapy (RT) planning, specifically regarding radiotherapy dose, technique, and organ‐at‐risk (OAR) constraints. The sessions also identified recurring educational gaps and systemic needs for improved multidisciplinary coordination. Conclusion: The virtual PROPRM model is a feasible and effective strategy for centralizing specialized expertise and improving QA in resource‐limited settings. By identifying systemic gaps and standardizing care, this framework offers a sustainable pathway toward reducing global disparities in childhood cancer outcomes.
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70213
Experience of Pediatric Radiation Oncology Peer Review Meetings: First Step Toward Centralizing Pediatric Radiotherapy in Pakistan
Introduction: Stark disparities in pediatric cancer outcomes persist between high and low sociodemographic index (SDI) regions due to fragmented healthcare systems and limited subspecialty expertise. In Pakistan, where pediatric radiation oncology expertise is not widely available, ensuring quality assurance (QA) is critical to mitigate errors that can lead to suboptimal treatment outcomes and long‐term consequences in children. To address this, virtual Pediatric Radiation Oncology Peer Review Meetings (PROPRMs) were initiated in 2022 to foster collaborative decision‐making and standardize treatment across the country. Methods: This study analyzed data from June 2022 to March 2025 from virtual PROPRM sessions organized by the Aga Khan University Hospital. Multidisciplinary meetings involving radiation and pediatric oncologists from multiple centers across the country transitioned from monthly to fortnightly. Case volume, clinical diagnoses, and management adjustments were documented and analyzed using descriptive statistics. Results: A total of 130 cases were reviewed across 46 sessions. The most common diagnostic categories were soft‐tissue sarcomas (33.8%) and bone tumors (16.2%). Notably, consensus‐driven changes in management were recommended in 70.8% of cases. The primary modifications (43.1%) directly involved radiation therapy (RT) planning, specifically regarding radiotherapy dose, technique, and organ‐at‐risk (OAR) constraints. The sessions also identified recurring educational gaps and systemic needs for improved multidisciplinary coordination. Conclusion: The virtual PROPRM model is a feasible and effective strategy for centralizing specialized expertise and improving QA in resource‐limited settings. By identifying systemic gaps and standardizing care, this framework offers a sustainable pathway toward reducing global disparities in childhood cancer outcomes.
- Open Access
- 1 December 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (12) , 4633-4638
Evaluating the Impact of Transitioning from Weekly to Daily Peer Review in Radiation Oncology
Peer review is essential for quality assurance (QA) in radiation therapy, addressing the variability among clinicians in defining treatment target volumes. At our institution, weekly peer review meetings (PRMs) were initially conducted on Fridays, but the need for more robust review led to the implementation of PRMs on a daily basis. These daily sessions aim to enhance quality by routinely discussing each radiation therapy plan with a team of radiation oncologists. In this study, the impact of daily PRMs on radiation oncology planning was assessed by analyzing changes suggested during these meetings. Treatment plans for 249 patients were reviewed from April to September 2022. During PRMs, each plan was reviewed and modifications were categorized as no change, minor change, major change, or missing contour, with further stratification by target volumes, treatment field, radiation doses and treatment decisions. A total of 249 cases were reviewed. The largest proportion of discussed plans comprised head & neck cancers (n= 79, 31.7%), thorax (n=55, 22.1%) followed by brain and pelvis (each n=39, 15.7%). Most of the plans i.e., 190 (76.3%) were based on IMRT/VMAT. PRM changes were suggested in 114 (45.7%) cases, where 78 (31.3%) were minor and 36 (14.5%) were major changes. In most cases the changes were suggested in CTV i.e., 62 (24.9%) while PTV modifications were suggested in 21 (8.4%) of the cases during PRM discussion. Among all, head and neck was the region with most frequent PRM changes, suggestions 53 (57.6%) followed by pelvis 18 (19.5%). Peer review is a vital component of quality assurance in radiation oncology, helping to identify and correct potential errors, standardize care, and enhance patient safety. It also promotes multidisciplinary collaboration and serves as a valuable educational tool, ultimately supporting more effective and individualized treatment.
- 1 December 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (12) , 4633-4638
Open AccessEvaluating the Impact of Transitioning from Weekly to Daily Peer Review in Radiation Oncology
Peer review is essential for quality assurance (QA) in radiation therapy, addressing the variability among clinicians in defining treatment target volumes. At our institution, weekly peer review meetings (PRMs) were initially conducted on Fridays, but the need for more robust review led to the implementation of PRMs on a daily basis. These daily sessions aim to enhance quality by routinely discussing each radiation therapy plan with a team of radiation oncologists. In this study, the impact of daily PRMs on radiation oncology planning was assessed by analyzing changes suggested during these meetings. Treatment plans for 249 patients were reviewed from April to September 2022. During PRMs, each plan was reviewed and modifications were categorized as no change, minor change, major change, or missing contour, with further stratification by target volumes, treatment field, radiation doses and treatment decisions. A total of 249 cases were reviewed. The largest proportion of discussed plans comprised head & neck cancers (n= 79, 31.7%), thorax (n=55, 22.1%) followed by brain and pelvis (each n=39, 15.7%). Most of the plans i.e., 190 (76.3%) were based on IMRT/VMAT. PRM changes were suggested in 114 (45.7%) cases, where 78 (31.3%) were minor and 36 (14.5%) were major changes. In most cases the changes were suggested in CTV i.e., 62 (24.9%) while PTV modifications were suggested in 21 (8.4%) of the cases during PRM discussion. Among all, head and neck was the region with most frequent PRM changes, suggestions 53 (57.6%) followed by pelvis 18 (19.5%). Peer review is a vital component of quality assurance in radiation oncology, helping to identify and correct potential errors, standardize care, and enhance patient safety. It also promotes multidisciplinary collaboration and serves as a valuable educational tool, ultimately supporting more effective and individualized treatment.
- Open Access
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32155
Selection of the Most Appropriate Radiation Treatment Modality for Children's Cancers: A Paediatric Radiation Oncology Society (PROS) Position Paper on the Ethical Utilization of Proton Therapy
Background: Proton beam therapy (PBT) offers dosimetric advantages in pediatric radiotherapy by reducing radiation exposure to healthy tissues. However, broad implementation raises important ethical, logistical, and equity considerations, especially in settings with limited access to advanced technologies. Procedure: This position paper by the Paediatric Radiation Oncology Society (PROS) reviews the clinical rationale for selecting radiotherapy modalities in children, with a specific focus on ethical utilization of PBT. The document synthesizes evidence on the benefits and limitations of modern photon and proton therapies, explores disparities in access, outlines the role of local pediatric radiation oncologists, and addresses the impact of industry‐driven messaging on family decision‐making. Results: While PBT offers clinical benefit in selecting pediatric cancers, high‐quality photon‐based treatments such as IMRT and VMAT remain effective and widely accessible alternatives. The referral and evaluation process for PBT is complex and may introduce treatment delays. Travel and financial burdens can exacerbate disparities. PROS underscores the critical role of local pediatric radiation oncologists in counseling families, and calls for balanced, evidence‐based communication from providers and industry stakeholders. Conclusions: PROS advocates for an ethical, equitable, and evidence‐informed approach to radiotherapy modality selection in children, reflecting holistic considerations beyond dosimetry. Proton therapy should be pursued when clinically indicated and accessible without compromising timely care. Investment in a comprehensive radiation therapy infrastructure, including professional education, collaborative research, and responsible public messaging, is essential to optimize pediatric cancer outcomes globally.
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e32155
Open AccessSelection of the Most Appropriate Radiation Treatment Modality for Children's Cancers: A Paediatric Radiation Oncology Society (PROS) Position Paper on the Ethical Utilization of Proton Therapy
Background: Proton beam therapy (PBT) offers dosimetric advantages in pediatric radiotherapy by reducing radiation exposure to healthy tissues. However, broad implementation raises important ethical, logistical, and equity considerations, especially in settings with limited access to advanced technologies. Procedure: This position paper by the Paediatric Radiation Oncology Society (PROS) reviews the clinical rationale for selecting radiotherapy modalities in children, with a specific focus on ethical utilization of PBT. The document synthesizes evidence on the benefits and limitations of modern photon and proton therapies, explores disparities in access, outlines the role of local pediatric radiation oncologists, and addresses the impact of industry‐driven messaging on family decision‐making. Results: While PBT offers clinical benefit in selecting pediatric cancers, high‐quality photon‐based treatments such as IMRT and VMAT remain effective and widely accessible alternatives. The referral and evaluation process for PBT is complex and may introduce treatment delays. Travel and financial burdens can exacerbate disparities. PROS underscores the critical role of local pediatric radiation oncologists in counseling families, and calls for balanced, evidence‐based communication from providers and industry stakeholders. Conclusions: PROS advocates for an ethical, equitable, and evidence‐informed approach to radiotherapy modality selection in children, reflecting holistic considerations beyond dosimetry. Proton therapy should be pursued when clinically indicated and accessible without compromising timely care. Investment in a comprehensive radiation therapy infrastructure, including professional education, collaborative research, and responsible public messaging, is essential to optimize pediatric cancer outcomes globally.
- 30 October 2025
- Published by Elsevier in Medical Dosimetry
- Vol. 51 (1) , 136-144
Impact of bowel preparation compliance on interfractional rectal diameter variation during prostate cancer radiotherapy
- 30 October 2025
- Published by Elsevier in Medical Dosimetry
- Vol. 51 (1) , 136-144
Impact of bowel preparation compliance on interfractional rectal diameter variation during prostate cancer radiotherapy
- 25 October 2025
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 1-13
Clinical profile and outcomes of pediatric ependymoma: a 10-year retrospective analysis from a resource-limited setting
Background Pediatric ependymomas account for 6–10% of central nervous system tumors in children and are the third most common pediatric brain tumor. However, survival and outcome data from low- and middle-income countries (LMICs), particularly in South Asia, are limited. This study aims to evaluate the clinical profile, treatment approaches, and survival outcomes of pediatric patients with ependymoma in a tertiary care setting in Pakistan. Methods This retrospective cohort study included 48 pediatric and young adult patients (aged 0–21 years) diagnosed with ependymoma and treated at Aga Khan University Hospital, Karachi, from January 2012 to December 2021. Data were collected on demographics, clinical presentation, tumor location, histopathology, treatment modalities, and follow-up. Survival analysis was conducted using SPSS version 23.0, with Kaplan-Meier estimates for overall survival (OS) and progression-free survival (PFS), and comparisons performed using the log-rank test. Results Of the 48 patients, 64.6% were male, with a median age of 7.5 years. Presenting symptoms included headache and vomiting (43.75%), limb weakness (25%), back pain (20.83%), and ataxia (18.75%). Tumors were located in the posterior fossa (50%), supratentorial region (29.2%), and spinal cord (20.8%). All patients underwent surgical resection; postoperative complications were noted in a subset. Histopathological subtypes included anaplastic (62.5%), classic (33.3%), and myxopapillary ependymoma (4.2%). Adjuvant radiotherapy was given to 62.5% and chemotherapy to 10.4%. The 10-year overall survival (OS) and progression-free survival (PFS) rates were 79.2% and 66.7%, respectively. Tumor recurrence was observed in 18.8% of cases. Conclusion Multimodal treatment yielded favorable outcomes despite resource constraints. Early diagnosis and individualized management are crucial for enhancing survival in low- and middle-income country (LMIC) settings.
- 25 October 2025
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 1-13
Clinical profile and outcomes of pediatric ependymoma: a 10-year retrospective analysis from a resource-limited setting
Background Pediatric ependymomas account for 6–10% of central nervous system tumors in children and are the third most common pediatric brain tumor. However, survival and outcome data from low- and middle-income countries (LMICs), particularly in South Asia, are limited. This study aims to evaluate the clinical profile, treatment approaches, and survival outcomes of pediatric patients with ependymoma in a tertiary care setting in Pakistan. Methods This retrospective cohort study included 48 pediatric and young adult patients (aged 0–21 years) diagnosed with ependymoma and treated at Aga Khan University Hospital, Karachi, from January 2012 to December 2021. Data were collected on demographics, clinical presentation, tumor location, histopathology, treatment modalities, and follow-up. Survival analysis was conducted using SPSS version 23.0, with Kaplan-Meier estimates for overall survival (OS) and progression-free survival (PFS), and comparisons performed using the log-rank test. Results Of the 48 patients, 64.6% were male, with a median age of 7.5 years. Presenting symptoms included headache and vomiting (43.75%), limb weakness (25%), back pain (20.83%), and ataxia (18.75%). Tumors were located in the posterior fossa (50%), supratentorial region (29.2%), and spinal cord (20.8%). All patients underwent surgical resection; postoperative complications were noted in a subset. Histopathological subtypes included anaplastic (62.5%), classic (33.3%), and myxopapillary ependymoma (4.2%). Adjuvant radiotherapy was given to 62.5% and chemotherapy to 10.4%. The 10-year overall survival (OS) and progression-free survival (PFS) rates were 79.2% and 66.7%, respectively. Tumor recurrence was observed in 18.8% of cases. Conclusion Multimodal treatment yielded favorable outcomes despite resource constraints. Early diagnosis and individualized management are crucial for enhancing survival in low- and middle-income country (LMIC) settings.